Long non‐coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer

Owing to the small sample size and short follow-up period in the TCGA cohort, prognostic associations of the LNC6 subtypes were evaluated in independent public cohorts (n = 1,933; Table S1). Because lncRNA expression data from RNA sequencing are available for only TCGA among large-scale cohorts, we used LNC6 subtype-specific mRNA gene signature (Figures 1A and 1B). In agreement with this, silencing ZNF667-AS1 increased the expression of an epithelial marker (E-cadherin) and decreased the expression of mesenchymal markers (N-cadherin and vimentin) (Figure 4A). [...]this increased sensitivity to drugs commonly used for GC treatment – oxaliplatin and 5-FU (Figure 4B). Significant association of lncRNA expression with prognosis and therapeutic responses indicate that it could be used to elaborate precision medicine for GC. [...]functional association of a lncRNA with clinically relevant phenotypes supports the notion of lncRNA-targeting therapeutics.